score_bin	sensitive_predictive_implication	resistance_predictive_implication	prognostic_predictive_implication	feature_type	feature	alteration_type	alteration	tumor_f	total_coverage	exac_af	exac_common	clinvar	sensitive_score_bin	sensitive_therapy_name	sensitive_therapy_type	sensitive_description	sensitive_citation	sensitive_url	resistance_score_bin	resistance_therapy_name	resistance_therapy_type	resistance_description	resistance_citation	resistance_url	prognostic_score_bin	favorable_prognosis	prognostic_description	prognostic_citation	prognostic_url	number_germline_mutations_in_gene	validation_total_coverage	validation_tumor_f	validation_detection_power	feature_display	preclinical_efficacy_observed	patient_id	tumor_sample_barcode	normal_sample_barcode
Putatively Actionable	Clinical trial			Copy Number	PIK3CA	Amplification				0.0	0.0		Putatively Actionable	Pictilisib	Targeted therapy	A heavily-pretreated, platinum-refractory ovarian cancer patient with PIK3CA amplification achieved radiologically stable disease for four months in a phase 1 clinical trial of pictisilib in solid tumors (RP2D of 330mg daily).	Sarker D, Ang JE, Baird R, et al. First-in-human phase I study of pictilisib (GDC-0941), a potent pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors. Clin Cancer Res. 2015;21(1):77-86.	https://doi.org/10.1158/1078-0432.CCR-14-0947												0				PIK3CA Amplification	1.0	SC_9027	SC_9027-Tumor	
Investigate Actionability - High	Clinical trial			Somatic Variant	ATM	Nonsense	p.Q1970*	0.0704	71.0	0.0	0.0		Investigate Actionability - High	BAY 1895344	Targeted therapy	The ATR inhibitor BAY 1895344 is tolerated at biologically active doses with anti-tumor activity against cancers with certain DDR defects, including ATM protein loss, in patients with advanced metastatic solid tumors resistant or refractory to standard treatment, with and without DDR defects.	De Bono JS, Tan DSP, Caldwell R, et al. First-in-human trial of the oral ataxia telangiectasia and Rad3-related (ATR) inhibitor BAY 1895344 in patients (pts) with advanced solid tumors. JCO. 2019; 37(15_suppl):3007-3007.	https://10.1200/JCO.2019.37.15_suppl.3007												0	0.0	0.0	0.0	ATM p.Q1970* (Nonsense)		SC_9027	SC_9027-Tumor	SC_9027-Normal
Investigate Actionability - High		Guideline		Somatic Variant	ABL1	Missense	p.A633S	0.0176	569.0	0.0	0.0								Investigate Actionability - High	Dasatinib	Targeted therapy	Selection of alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR-ABL1 mutant CML may be based on mutantion profile.	National Comprehensive Cancer Network. Chronic Myeloid Leukemia NCCN Evidence Blocks (Version 1.2019). https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf. Accessed August 9th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf						0	0.0	0.0	0.0	ABL1 p.A633S (Missense)		SC_9027	SC_9027-Tumor	SC_9027-Normal
Investigate Actionability - High			Inferential	Aneuploidy	Whole genome doubling																				Investigate Actionability - High	0.0	WGD was associated with adverse survival pan-cancer in patients with advanced disease and in cancers with heterogeneous clinical outcomes, even following the development of metastasis.	Bielski CM, Zehir A, Penson AV, et al. Genome doubling shapes the evolution and prognosis of advanced cancers Nat Genet. 2018; 50(8):1189-1195.	https://doi.org/10.1038/s41588-018-0165-1	0						SC_9027		
Investigate Actionability - Low	Clinical trial	Clinical evidence		Somatic Variant	BRCA2	Frameshift	p.K3083fs	0.38299999999999995	47.0	0.0	0.0		Investigate Actionability - Low	Olaparib	Targeted therapy	Patients with chemotherapy-refractory prostate cancer have higher response rates to PARP inhibitor therapy in the presence of DNA repair mutations, particularly concomittant with platinum-sensitive disease. Platinum-resistant disease partially abrogates olaparib sensitvity in the setting of BRCA1 and BRCA2 mutations.	Mateo J, Carreira S, Sandhu S, et al. DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. N Engl J Med. 2015;373(18):1697-708.	https://doi.org/10.1056/NEJMoa1506859	Investigate Actionability - Low	Olaparib	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677						0	0.0	0.0	0.0	BRCA2 p.K3083fs (Frameshift)	0.0	SC_9027	SC_9027-Tumor	SC_9027-Normal
Biologically Relevant				Somatic Variant	ROS1	Splice Site	p.*TV147fs	0.23	100.0	0.0	0.0																			0	0.0	0.0	0.0	ROS1 p.*TV147fs (Splice Site)		SC_9027	SC_9027-Tumor	SC_9027-Normal
Biologically Relevant				Microsatellite Stability	Supporting variants		PRDM2 p.703_704insP (Insertion), MSH3 p.AAAAAA52del (Deletion)																							0				Supporting variants: PRDM2 p.703_704insP (Insertion), MSH3 p.AAAAAA52del (Deletion)		SC_9027		
Biologically Relevant				Mutational Signature	COSMIC Signature 1		0.276																							0				COSMIC Signature 1 (28%)		SC_9027		
Biologically Relevant				Mutational Signature	COSMIC Signature 6		0.209																							0				COSMIC Signature 6 (21%)		SC_9027		
